Clinical Trials Evaluating Calcium Channel Blockers Compared with Diuretic or β-Blocker.
| Study Endpoints | STOP-210 RR (95% CI)* | INSIGHT11 RR (95% CI)* | NORDIL12 RR (95% CI)* |
|---|---|---|---|
| Combined primary endpoint | |||
| Fatal myocardial infarction, fatal stroke, or other fatal cardiovascular disease | 0.97 (0.80–1.17) | ||
| Death from any cardiovascular or cerebrovascular cause; or nonfatal myocardial infarction, stroke, or heart failure | 1.10 (0.91–1.34) | ||
| Fatal and nonfatal stroke, fatal and nonfatal stroke myocardial infarction, or other cardiovascular death | 1.00 (0.87–1.15) | ||
| Other endpoints | |||
| Myocardial infarction | Fatal and nonfatal: 1.18 (0.95–1.47) | Fatal: 3.22† (1.18–8.80) Nonfatal: 1.09 (0.76–1.58) | Fatal: 1.10 (0.64–1.88) Fatal and nonfatal: 1.16 (0.94–1.44) |
| Stroke | Fatal and nonfatal: 0.88 (0.73–1.06) | Fatal: 1.09 (0.48–2.48) Nonfatal: 0.87 (0.61–1.26) | Fatal: 0.96 (0.52–1.74) Fatal and nonfatal: 0.8 (0.65–0.99) |
| All major cardiovascular events | 0.99 (0.87–1.12) | 1.11 (0.90–1.36) | 1.04 (0.91–1.18) |
| Cardiovascular mortality | 0.97 (0.80–1.17) | 1.16 (0.80–1.69) | 1.11 (0.87–1.43) |
| Total mortality | 0.99 (0.86–1.15) | 1.01 (0.80–1.27) | 1.00 (0.83–1.20) |
RR = relative risk, CI = confidence interval.
* Calcium channel blocker compared with diuretic or β-blocker.
† P = .017.